Edward Van Den Brink, PhD

Director, Antibody Discovery at Genmab

Dr. van den Brink has a wide experience in the discovery, characterization and development of therapeutic antibodies in various disease areas. After completion of his PhD at Sanquin/University of Amsterdam in 2000 and a postdoctoral fellowship at American Red Cross, he continued his career in the biopharmaceutical industry. First at Crucell, now Janssen Vaccines, where he was involved in the discovery of neutralizing antibodies against emerging viruses including SARS-CoV-1 and avian influenza. In his current role as Director Antibody Discovery at Genmab, he is responsible for the generation and characterization of target specific antibody panels. By combining these panels with Genmab’s proprietary antibody format, novel product concepts are created that form the basis for further drug development.